Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer
Authors:
- Amy KwanAKAmy Kwan
- Faith HowardFHFaith Howard
- Natalie WinderNWNatalie Winder
- Emer AtkinsonEAEmer Atkinson
- Ameera JailaniAmeera Jailani
- Priya B. PatelPPPriya B. Patel
- Richard AllenRARichard Allen
- Penelope D. OttewellPenelope D. Ottewell
- Gary C. ShawGSGary C. Shaw
- Joe ConnerJCJoe Conner
- Caroline WilsonCWCaroline Wilson
- Sanjay K. SrivastavaSanjay K. Srivastava
Open Access
- 21 October 2022
- journal article
- research article
- Published by MDPI AG in Future Pharmacology
- Vol. 2 (4) , 444-459
Abstract
Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host’s systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective treatment for mammary cancer. However, intravenous administration of a virus has the potential to result in neutralization and sequestration of the virus which may reduce efficacy. Here, we show that the oncolytic virus HSV1716 can be administered within a cellular carrier (macrophages). PyMT and 4T1 murine mammary cancer cell lines were implanted into immuno-competent murine models (orthotopic primary, early metastatic and brain metastasis models). HSV1716 or macrophages armed with HSV1716 (M-HSV1716) were administered intravenously, and tumour size was quantified using caliper measurement or bioluminescence imaging. Administration of M-HSV1716 led to tumour shrinkage and increased the survival of animals. Furthermore, these results were achieved with a 100-fold lower viral load, which has the potential for decreased toxicity. Our results demonstrate that M-HSV1716 is associated with activity against murine mammary cancers and provides an alternative platform for the systemic delivery of OV.Keywords
Funding Information
- Cancer Research UK (C25574/A24321)
- Sheffield Teaching Hospitals (12053)
- Team Verrico (MS/149394)
This publication has 36 references indexed in Scilit:
- Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastasesProceedings of the National Academy of Sciences, 2013
- Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or IrradiationCancer Research, 2013
- The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patientsBMC Cancer, 2012
- Systemic Delivery of Oncolytic Viruses: Hopes and HurdlesAdvances in Virology, 2012
- Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancerGenes & Development, 2011
- Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate TumorsCancer Research, 2011
- Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer TherapyMolecular Therapy, 2009
- A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 2006
- Viral and host cofactors facilitate HIV-1 replication in macrophagesJournal of Leukocyte Biology, 2003
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002